PMID- 10416594
OWN - NLM
STAT- MEDLINE
DCOM- 19990812
LR  - 20211203
IS  - 0008-5472 (Print)
IS  - 0008-5472 (Linking)
VI  - 59
IP  - 14
DP  - 1999 Jul 15
TI  - The S387Y mutations of the transforming growth factor-beta receptor type I gene 
      is uncommon in metastases of breast cancer and other common types of 
      adenocarcinoma.
PG  - 3363-4
AB  - Recently, mutations of the transforming growth factor-beta receptor type I gene 
      have been reported to occur at high frequency in breast cancer metastases, with 
      all mutations being an identical C to A transversion at nucleotide 1160 of the 
      gene (T. Chen et al, Cancer Res., 58: 4805-4810, 1998). This mutation would 
      result in a serine to tyrosine substitution at codon 387 (S387Y) and would 
      reportedly disrupt receptor function. Because this mutation reportedly occurred 
      at high frequency in breast cancer metastases (42%) and much less frequently in 
      primary breast cancer tumors (6%), this would seem to represent a pivotal genetic 
      alteration in breast cancer progression. To further investigate the possible role 
      of this specific genetic alteration in the progression of breast cancer and other 
      forms of adenocarcinoma, we analyzed 20 breast cancer metastases, 15 lung 
      adenocarcinoma metastases, and 13 colorectal cancer metastases for possible 
      mutations at this site. Using both single-strand conformation polymorphism 
      screening and sequencing, we found no mutations of this gene in any of our 
      samples. Our results suggest the S387Y mutation of the transforming growth 
      factor-beta receptor type I gene is not common in these types of human cancers.
FAU - Anbazhagan, R
AU  - Anbazhagan R
AD  - Department of Oncology, The Johns Hopkins University School of Medicine, 
      Baltimore, Maryland 21224, USA.
FAU - Bornman, D M
AU  - Bornman DM
FAU - Johnston, J C
AU  - Johnston JC
FAU - Westra, W H
AU  - Westra WH
FAU - Gabrielson, E
AU  - Gabrielson E
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Res
JT  - Cancer research
JID - 2984705R
RN  - 0 (DNA, Neoplasm)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Receptors, Transforming Growth Factor beta)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
RN  - EC 2.7.11.30 (Activin Receptors, Type I)
RN  - EC 2.7.11.30 (Receptor, Transforming Growth Factor-beta Type I)
SB  - IM
MH  - *Activin Receptors, Type I
MH  - Adenocarcinoma/classification/*genetics/*secondary
MH  - *Amino Acid Substitution
MH  - Breast Neoplasms/*genetics/pathology
MH  - Colorectal Neoplasms/*genetics/pathology
MH  - DNA, Neoplasm/genetics
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*genetics/pathology
MH  - Male
MH  - Neoplasm Metastasis/*genetics
MH  - Neoplasm Proteins/*genetics
MH  - *Point Mutation
MH  - Polymorphism, Single-Stranded Conformational
MH  - Protein Serine-Threonine Kinases/*genetics
MH  - Receptor, Transforming Growth Factor-beta Type I
MH  - Receptors, Transforming Growth Factor beta/*genetics
MH  - Structure-Activity Relationship
EDAT- 1999/07/23 00:00
MHDA- 1999/07/23 00:01
CRDT- 1999/07/23 00:00
PHST- 1999/07/23 00:00 [pubmed]
PHST- 1999/07/23 00:01 [medline]
PHST- 1999/07/23 00:00 [entrez]
PST - ppublish
SO  - Cancer Res. 1999 Jul 15;59(14):3363-4.